169 related articles for article (PubMed ID: 32957363)
1. Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol.
Cheon C; Ko SG
Medicine (Baltimore); 2020 Sep; 99(38):e22228. PubMed ID: 32957363
[TBL] [Abstract][Full Text] [Related]
2. Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol.
Cheon C; Kang S; Ko Y; Kim M; Jang BH; Shin YC; Ko SG
BMJ Open; 2018 Aug; 8(8):e019502. PubMed ID: 30082340
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer.
Cheon C; Ko SG
Integr Cancer Ther; 2020; 19():1534735420911442. PubMed ID: 32186413
[No Abstract] [Full Text] [Related]
4. The immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) or its active constituent nodakenin.
Han NR; Kim KC; Kim JS; Ko SG; Park HJ; Moon PD
J Ethnopharmacol; 2022 Mar; 285():114893. PubMed ID: 34875347
[TBL] [Abstract][Full Text] [Related]
5. State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent.
Lee K; Youn BY; Choi YJ; Moon S; Im J; Cho K; Ko SG; Cheon C
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205836
[TBL] [Abstract][Full Text] [Related]
6. Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling.
Choi YK; Cho SG; Woo SM; Yun YJ; Park S; Shin YC; Ko SG
Mediators Inflamm; 2014; 2014():492173. PubMed ID: 24976685
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
Jeong MS; Lee KW; Choi YJ; Kim YG; Hwang HH; Lee SY; Jung SE; Park SA; Lee JH; Joo YJ; Cho SG; Ko SG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445110
[TBL] [Abstract][Full Text] [Related]
8. SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway.
Choi YJ; Choi YK; Lee KM; Cho SG; Kang SY; Ko SG
BMC Complement Altern Med; 2016 Dec; 16(1):507. PubMed ID: 27927199
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
10. SH003‑induced G1 phase cell cycle arrest induces apoptosis in HeLa cervical cancer cells.
Lee KM; Lee K; Choi YK; Choi YJ; Seo HS; Ko SG
Mol Med Rep; 2017 Dec; 16(6):8237-8244. PubMed ID: 28944910
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
12. SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes.
Choi YK; Cho SG; Choi YJ; Yun YJ; Lee KM; Lee K; Yoo HH; Shin YC; Ko SG
Oncotarget; 2017 Oct; 8(51):88386-88400. PubMed ID: 29179443
[TBL] [Abstract][Full Text] [Related]
13. SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells.
Kim TW; Cheon C; Ko SG
Cell Death Dis; 2020 Sep; 11(8):717. PubMed ID: 32879309
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
15. The Mixture of Natural Products SH003 Exerts Anti-Melanoma Effects through the Modulation of PD-L1 in B16F10 Cells.
Han NR; Park HJ; Ko SG; Moon PD
Nutrients; 2023 Jun; 15(12):. PubMed ID: 37375695
[TBL] [Abstract][Full Text] [Related]
16. SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2.
Choi HS; Kim MK; Lee K; Lee KM; Choi YK; Shin YC; Cho SG; Ko SG
Oncotarget; 2016 May; 7(22):32969-79. PubMed ID: 27105528
[TBL] [Abstract][Full Text] [Related]
17. Analgesic Effect of SH003 and
Lee JH; Kim B; Ko SG; Kim W
Curr Issues Mol Biol; 2022 Jan; 44(2):718-730. PubMed ID: 35723335
[TBL] [Abstract][Full Text] [Related]
18. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Bayet-Robert M; Kwiatkowski F; Leheurteur M; Gachon F; Planchat E; Abrial C; Mouret-Reynier MA; Durando X; Barthomeuf C; Chollet P
Cancer Biol Ther; 2010 Jan; 9(1):8-14. PubMed ID: 19901561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
